A tool for the assessment of hand involvement in rheumatic disorders in daily routine – the SF-SACRAH (short form score for the assessment and quantification of chronic rheumatic affections of the hands)  by Rintelen, B. et al.
Osteoarthritis and Cartilage (2009) 17, 59e63
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2008.05.003
International
Cartilage
Repair
SocietyA tool for the assessment of hand involvement in rheumatic disorders in
daily routine e the SF-SACRAH (short form score for the assessment
and quantiﬁcation of chronic rheumatic affections of the hands)
B. Rintelen M.D., P. M. Haindl M.D., H. T. H. Mai M.D., J. Sautner M.D.,
A. Maktari M.D. and B. F. Leeb M.D., Director*
1st and 2nd Department of Medicine, Center for Rheumatology, Lower Austria,
State Hospital Korneuburg-Stockerau, Karl Landsteiner Institute for Clinical
Rheumatology, A-2000 Stockerau, Landstrasse 18, Austria
Summary
Objective: To establish a questionnaire for quantiﬁcation of hand involvement in osteoarthritis (OA) of the hands and rheumatoid arthritis (RA)
meeting daily routine requirements.
Patients and methods: The smallest number of questions of the modiﬁed score for the assessment and quantiﬁcation of chronic rheumatic
affections of the hands (M-SACRAH) providing reasonable reliability was identiﬁed by factor analysis and calculating Cronbach’s alpha,
subsequently resulting in a ﬁve-item scale, the short form-SACRAH (SF-SACRAH), which was then administered to 176 RA and 71 hand-
OA (HOA) patients simultaneously with the M-SACRAH. Additionally, patient’s satisfaction (PatSAT) with disease status was assessed (ac-
cording to the Austrian school marking system from 1 to 5). Gamma was calculated to assess the agreement of the SF-SACRAH with the M-
SACRAH and between the single corresponding questions of different formats. The Wilcoxon rank test was applied to estimate the
relationship between PatSAT and the SF-SACRAH.
Results: Alpha for the SF-SACRAH in 176 RA and 71 HOA patients amounted to 0.869 and to 0.897, respectively, indicating high internal
consistency. In both patient groups the SF-SACRAH was found to be signiﬁcantly correlated to the M-SACRAH (both Ps< 0.01). Agreement
between the corresponding questions of both scales was signiﬁcant in both patient groups by calculating gamma (average gamma 0.683 in
HOA and 0.847 in RA). PatSAT and SF-SACRAH values were highly signiﬁcantly correlated (P< 0.001) proving the score’s external validity.
Conclusion: The SF-SACRAH proved to be a brief and practicable tool to assess hand involvement in OA and RA meeting the requirements of
daily routine.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction (DASH), Michigan hand outcomes questionnaire (MHOQ),Rheumatoid arthritis (RA) and hand-osteoarthritis (OA)
(HOA) are the most common disorders causing hand
impairment in rheumatology1. Tender and swollen joint-
counts, patient’s global assessment (PatGA) or physician’s
global assessment (PhGA), and determination of laboratory
parameters as erythrocyte sedimentation rate (ESR) or
C-reactive protein (CRP) are mirroring disease activity,
but do not reﬂect, if only in part, the extent of functional
hand impairment, a decisive parameter for the patient’s
well being as well as for work disability2. Several question-
naires to quantify the hand involvement in rheumatic
diseases have been elaborated (superior limb section of ar-
thritis impact measurement scales (AIMS2), functional in-
dex for hand arthropathies (FIHOA), Duruoz hand index;
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59Cochin index and the Australian/Canadian osteoarthritis
hand index (AUSCAN)3e10).
We have developed a score for the assessment and
quantiﬁcation of chronic rheumatoid affections of the hands
(SACRAH)11, a questionnaire comprising 23 questions to
be answered by visual analogue scales (VASs:
0e100 mm) covering the following three domains: function,
joint stiffness and pain. This questionnaire was modiﬁed (M-
SACRAH) by reducing the number of questions resulting in
12 questions with a minimum of at least two questions
covering each domain12. However, all these questionnaires,
including the two SACRAHs, do not meet the requirements
to be applied in daily routine, as they either comprise too
many questions or are too difﬁcult and time consuming to
be calculated or both.
Therefore, we tried to develop a tool for the assessment
of hand involvement in rheumatic disorders which is easily
applicable in daily clinical practice. The new tool should
be easy to calculate and time sparing to complete while still
providing the most accurate data possible. Providing the
physician with sufﬁcient information about the disease
course and red ﬂags in case of deterioration can be
regarded the most important requirement for any routine
disease activity monitoring tool.
Table I
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Demographic dataQUESTIONNAIRE
Disease RA
(*median, range)
HOA
(*median, range)
No. of patients 179 71
Correctly completed 176 71
Age in Years *61 (32e80) *60 (41e74)
Gender (% female) 84 91
Disease duration in
months
*65 (5e600) *45 (4e480)
Rheumafactor
positive %
54.9 e
M-SACRAH *15.75 (0.0e88.0) *17.42 (1.2e88.1)
SF-SACRAH
DAS28
*1.6 (0.0e8.0) *1.6 (0.0e8.2)
3.84 (1.25e6.16) e
Time to complete
and evaluate SF-
SACRAH in
seconds
*45 (40e105) *40 (40e85)
PatGA *30 (0e100) *20 (0e73)
PhGA *25 (0e100) *20 (0e86)
PatSAT *3 (1e5) *2 (1e5)A comparative analysis of the M-SACRAH and the AUSCAN in 61
patients with HOA using factor analysis revealed a high degree of redun-
dancy of both questionnaires13. Therefore, we attempted to identify the
smallest number of questions of the M-SACRAH providing reasonable reli-
ability, indicated by a standardized item alpha >0.7 by combining the ques-
tions showing the highest item loadings. At the end of the process the
combination of ﬁve questions, three out of the function domain, and one
out of the pain and stiffness domain, respectively, namely question numbers
1, 4, 7, 9 and 12 of the M-SACRAH, were found to meet these criteria (Table
II). This newly established scale, the SF-SACRAH, was then investigated for
its psychometric properties. We compared it with the original SACRAH in
those 172 patients (69 with HOA, 103 with RA) who were assessed to create
the respective scale11, and to the M-SACRAH within the cohort investigated
for the creation of the latter12. After having proven internal consistency and
correlation with the mother instruments14, the format of the questionnaire
was changed from VASs to Likert-scales (LSs) from 0 to 10 in order to
enhance the applicability of the SF-SACRAH. Zero as an answer to the three
questions concerning function means ‘‘possible without any difﬁculty’’, 10
means ‘‘impossible’’; concerning stiffness a value of 0 indicates ‘‘no stiff-
ness’’, and 10 ‘‘unbearable stiffness’’ and very similar, in the last question
concerning pain 0 indicates ‘‘no pain’’ and 10 ‘‘unbearable pain’’.
While the M-SACRAH needs measuring of 12 VAS from 0 to 100 mm
followed by adding and dividing the sum by 12 (resulting in a range from 0.0
to 100.0), the SF-SACRAH is a sum up of the answers given to each question
with a subsequent division by ﬁve (the number of questions). Thus the SF-
SACRAH is easily calculated and ranges from 0 to 10. The questionnaire
was developed and applied in German language. The translated English ver-
sion in Table II is coined by the translation of the original SACRAH11.PATIENTSTo prove internal consistency and validity of the new instrument 179 RA pa-
tients and 71HOApatientswere included into this validation study. RApatients
were diagnosed according to the American RheumatismAssociation criteria15
(median age 61 years, range 32e80 years, 84% female) and HOA patients di-
agnosed according to the American College of Rheumatology criteria16 (me-
dian age 60 years, range 41e74 years, 91% female). All of the patients
presented at the outpatient department between May and September 2006
andgave their informed consent to be enrolled. All RApatientswere on therapy
with non-steroidal anti-inﬂammatory drugs (NSAIDs) either continuously or on
demand, 169 patients (96.3%) were on different disease modifying antirheu-
matic drugs (DMARDs). One hundred and eighteen patients (67.2%) received
additional low dose corticosteroids. Patients with Steinbrocker functional
stage III or IV were deliberately excluded from the study since they are depen-
dent on external assistance for most of the activities asked for in the functional
questions of the M-SACRAH. 71.8% (51) of the HOA patients were on three
monthly therapy with symptomatic slow acting drugs in osteoarthritis (SYSA-
DOA; condroitinsulphate or diacerein), all of them on NSAIDs or analgesics
on demand (for demographic data see Table I). Patients were asked to com-
plete the new SF-SACRAH and the M-SACRAH.
Patients were randomly assigned to complete one of the questionnaires
after initial instruction by a nurse or resident without further assistance during
the waiting period and the other one at the physician’s desk, which resulted
in an average time lag of 30 min upon completion of both questionnaires.
Moreover, patient’s satisfaction (PatSAT)17 with the disease status was
assessed according to the Austrian school marking system (1¼ excellent
to 5¼ unsatisfactory). PatGA and PhGA (both 0e100 mm VAS) were
recorded as well.STATISTICSInternal consistency testing was performed by calculating standardized
item alpha18. A value greater than 0.7 is commonly regarded a marker of
substantial reliability on a group level, for the individual application even
higher values were required19. The Spearman rank correlation was applied
to examine the relationship between SF-SACRAH and M-SACRAH levels.
Gamma as an ordinal symmetric measure was calculated to prove agree-
ment between the questions of the SF-SACRAH and the M-SACRAH,
respectively, as they have a different format. To reveal the relationship
between PatSAT and the SF-SACRAH and M-SACRAH levels the Wilcoxon
rank test was applied as PatSAT was shown to be not normally distributed
according to the KolmogoroveSmirnov accommodation.
Results
In the ﬁrst step of its development, the SF-SACRAH
appeared to provide high internal consistency (standardized
item alpha 0.731 and 0.837, respectively) and was highlysigniﬁcantly correlated to the M-SACRAH (r¼ 0.639,
P< 0.001) and signiﬁcantly to the original SACRAH
(r¼ 0.492, P< 0.001) in the respective patients cohorts11,12
[Fig. 1(a and b)]. Moreover, a highly signiﬁcant correlation of
the SF-SACRAH to PatGA (r¼ 0.784, P< 0.0001) and
PhGA (r¼ 0.646, P< 0.001) could be found.
In the second step all but three patients (179 with RA and
71 with HOA) completed the SF-SACRAH correctly. Three
out of the 179 RA patients, did not complete the M-SAC-
RAH correctly, writing comments instead of marking the
VAS or did not mark the VAS accurately. All others reported
no difﬁculties with ﬁlling in the forms. In 27 RA and 11 HOA
patients the time to complete the SF-SACRAH question-
naire and the time to calculate were measured. As in RA
patients as well in HOA patients this procedure was ﬁnal-
ized in less than 1 min (see Table I).
The median SF-SACRAH amounted to 1.6 (0.0e8.0) in
the 179 RA and to 1.6 (0.0e8.2) in the 71 HOA patients.
The respective M-SACRAH values were 15.75 (0.0e88.0)
in RA and 17.42 (1.2e86.1) in the patients with HOA.
The mean disease activity score (DAS28) in the RA pa-
tients was 3.84 (1.25e6.16), indicating overall moderate
disease activity. Mean satisfaction with disease status
was 3 in the RA-patient group and 2 in the HOA patient
group (range 1e5 in both groups).
The SF-SACRAH was found to be highly correlated to the
M-SACRAH in the RA (n¼ 179) as well as in the HOA
(n¼ 71) patient group (r¼ 0.846 for RA and 0.699 for
HOA; both Ps< 0.001) according to the Spearman rank
correlation [Fig. 2(a and b)].
As the questions’ format was changedwith the invention of
the SF-SACRAH, not only the agreement between the ﬁnal
scores, but also between the single questions of theSF-SAC-
RAH and the corresponding ones of the M-SACRAH was of
interest. For this reason gamma as a symmetrical ordinal
measure was calculated. In the HOA group all ﬁve questions
of the SF-SACRAHwere in highly signiﬁcant agreement with
the respective ones of the M-SACRAH (average gamma
0.683, all Ps< 0.001). The average gamma for the RA group
amounted to 0.847 (P for all questions <0.001).
Alpha as a measure for internal consistency was 0.869
for SF-SACRAH in RA patients and 0.897 for HOA patients,
respectively. Both values reasonably surpass the lower limit
of 0.7.
Table II
Questions of the SF-SACRAH (in the original German version and translated in English)
Domain SF-SACRAH: questionnaire in
German English
Function Wie schwierig war es fu¨r Sie innerhalb
der letzten 48 Stunden:
1. Die Haustu¨re mit dem Schlu¨ssel aufzusperren?
2. Den Reißverschluss zu o¨ffnen
beziehungsweise zu schließen?
3. Die Zeitung umzubla¨ttern?
How difﬁcult was it for you during the last 48 h to:
1. Unlock your door with a key?
2. To do up or undo a zip?
3. To turn the pages of the newspaper?
Stiffness 4. Wie stark war die Morgensteiﬁgkeit nach
dem ersten Aufwachen am Morgen?
4. How severe was your joint stiffness immediately
after waking up ﬁrst thing in the morning?
Pain 5. Wie stark waren Ihre Schmerzen in Ruhestellung
Ihrer Ha¨nde am Abend?
5. How severe was your pain at times of inactivity
in the evening?
61Osteoarthritis and Cartilage Vol. 17, No. 1The M-SACRAH proved to be a three-component score.
Question 1 of the M-SACRAH loaded on component 3
exclusively and was, therefore, included into the SF-SAC-
RAH (loading 0.949). Component 1 comprised question 2
to question 8 (loading range 0.602e0.845) with questions
4 and 7 loading strongest (0.785 and 0.845, respectively).
Questions 9e12 loaded on component 2 (0.587e0.888),
the questions of the M-SACRAH with the highest loadings,
namely 9 and 12 were included into the SF-SACRAH ques-
tionnaire (loading 0.808 and 0.888, respectively). Addition-
ally all questions chosen for the SF-SACRAH showed the
lowest loadings on the other components (0.002e0.246).
Due to the small differences in loading on the components
1 and 2, respectively, those questions can be regarded
redundant in this respect.
Factorial analysis of the SF-SACRAH by principal
component analysis revealed, that each single question
contributes signiﬁcantly (factor loading 0.682e0.931) to
the aggregate result with some minor differences in the
hierarchy of questions between RA and HOA.
To test for external validity the Wilcoxon rank test was
applied to analyze the relationship between PatSAT with
disease status and the SF-SACRAH. For both patient
groups a highly statistically signiﬁcant relationship between
the SF-SACRAH and PatSAT could be found (P< 0.001).Discussion
The main objective of this study was to assess whether
a shortened version of the SACRAH, the SF-SACRAH,
could be used as a completely patient administered tool
for daily monitoring. The SF-SACRAH should enable physi-
cians to get reliable information about the disease course
based on patients’ self report and it should be sensitive
enough to sound the alarm if deteriorations occur. A practi-
cable and easily calculable tool for assessment of hand
impairment can be regarded a prerequisite for effective
and successful patient monitoring in clinical routine. It has
been shown that close monitoring with validated tools
improves the outcome of RA patients20.
In fact a lot of tools are available for assessment of hand
involvement in rheumatic diseases3e10. Nevertheless, all of
them do not meet the requirements for daily practice as they
miss crucial attributes: they are either too long or need
complicated calculation, or both. Completing and calculat-
ing the SF-SACRAH is done in less than 1 min. In contrast,
the median completion time for the M-SACRAH appearedto be 1 min 35 s (range 1 min 20 s to 2 min 55 s),11 and
evaluation is also complicated and time consuming because
of the VASs. Other scores are more time consuming
as for example the mean time to perform the FIHOA
takes 2.5 min4.
The SF-SACRAH’s predecessors, the SACRAH and the
M-SACRAH, have been shown to be valid in expressing
hand involvement in RA and HOA patients and they showed
to be sensitive to change in RA patients. The relations of
these two instruments to the other available questionnaires
are discussed in the original papers11,12. One fact should be
emphasized: the AUSCAN was also validated for HOA in
a Likert scaled format (AUSCAN LK 3.0), but it comprises
more than ﬁve questions21. Therefore, we felt justiﬁed to
presume that the application of statistical procedures such
as factorial analysis and reliability analysis of the M-
SACRAH could ultimately result in a short and reliable,
patient orientated tool, which can be used in daily routine.
However, would this success hold true, when the new
instrument was applied in daily routine and compared with
the M-SACRAH? Alpha as a measure of the SF-SACRAH’s
reliability in the RA and HOA patients investigated was
above 0.8, which can be regarded the threshold of internal
consistency on an individual basis. Moreover, alpha usually
increases with the number of items and can be also
regarded a measure of redundancy. Though, a tool com-
prising ﬁve items and providing alpha levels >0.8 cannot
easily be denominated redundant.
Given the results of the principal component analysis of
the SF-SACRAH the choice of the questions turned out to
be an appropriate one. All items contribute signiﬁcantly to
the aggregate result without essential differences with
respect to their loading.
The change of the questions’ format from VAS in the M-
SACRAH to an 11-point ordinal scale in the SF-SACRAH
constituted another concern. This was done to enhance
applicability by avoiding time consuming measurement of
VAS in order to facilitate the calculation. By agreement
analysis an almost perfect agreement between the VAS of
the M-SACRAH and the ordinal scales of the SF-SACRAH
could be revealed. It is important to notify that in order to
avoid an interaction patients completed both questionnaires
after an interval of half an hour on average and in random
order.
Moreover, no major differences were seen on applying
the SF-SACRAH in HOA or RA patients and it proved to
be in accordance with patient’s satisfaction of disease
status. There is a slightly higher level of correlation between
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Fig. 2. (a) Correlation of the SF-SACRAH to the M-SACRAH in (a)
176 RA and (b) 71 HOA patients (Spearmen rank correlation).
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Fig. 1. (a) Correlation of the SF-SACRAH to the original SACRAH
and (b) of the SF-SACRAH to the M-SACRAH in the respective
(original) cohorts (Spearmen rank correlation).
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explanation could be due to the different numbers of
patients included in the two groups.
Of course there are shortcomings of this study: ﬁrst, the
effect of handedness was not investigated, but all functional
questions can be regarded directed primarily to the domi-
nant hand, while the two remaining questions (stiffness
and pain) are directed to both hands. Further investigationswill be necessary to explore whether there is a decisive
inﬂuence of dominant hand involvement. If impairment of
the dominant hand is apparent, the non-dominant hand is
the one to perform daily activities and this fact should per
se worsen the score, as difﬁculties increase. Second, the
SF-SACRAH’s sensitivity to change has to be proven in
a longitudinal study as with the original instruments11. Third,
the inﬂuence of global pain, assessed on a separate VAS,
was not investigated as assessment of pain in the evening
is part of the questionnaire (question 5). Further investiga-
tions will have to assess whether there is an explicit inﬂu-
ence of global pain on the score. However, it may be
anticipated that low individual pain thresholds, as known
e.g., for patients with ﬁbromyalgia, may increase the SF-
SACRAH results22,23. Forth, although in the meantime
a translated English version of the M-SACRAH was used
63Osteoarthritis and Cartilage Vol. 17, No. 1in aromatase inhibitor associated arthralgias in breast
cancer survivors24, the SF-SACRAH is not yet validated in
the English version. Nevertheless, the SF-SACRAH in the
German version already proved to be capable of screening
a nephrologic patient cohort for hand disorders at a sensitiv-
ity and speciﬁcity of 80%25.
In summary the effort to create a short and practicable
tool to measure hand impairment in rheumatic diseases,
in particular in RA and HOA, could be successfully ﬁnal-
ized. The SF-SACRAH is a patient orientated score which
provides high internal consistency and proved external
validity. The three questions concerning function (locking/
unlocking a door, fastening/unfastening a zip and turning
the pages of a newspaper) are easy to be answered by ev-
erybody since these activities have to be performed every-
day by females and males. The time necessary to
complete and evaluate the SF-SACRAH was found to be
lower than 1 min.
Rheumatology as a discipline has to live with the fact that
hard and uninﬂuenced parameters for disease activity
monitoring are not available26. The SF-SACRAH, however,
could constitute a possibility for routine monitoring of some
rheumatic diseases, in particular HOA, which constitutes
a disease, where an improvement of treatment as well as
the monitoring strategies deems necessary. And it may be
a tool not only for rheumatologists, but also and maybe
primarily, for non-rheumatologists.Conﬂict of interest
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